Total Payments
$2,035
2024 Payments
$155.64
Companies
16
Transactions
117
Medicare Patients
1,851
Medicare Billing
$305,784
Payment Breakdown by Category
Food & Beverage$1,895 (93.1%)
Education$140.62 (6.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,895 | 114 | 93.1% |
| Education | $140.62 | 3 | 6.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $603.12 | 29 | $0 (2020) |
| PFIZER INC. | $449.38 | 41 | $0 (2020) |
| Novo Nordisk Inc | $221.00 | 2 | $0 (2024) |
| Allergan Inc. | $151.15 | 8 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $114.43 | 8 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $106.18 | 6 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $78.54 | 6 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $76.20 | 4 | $0 (2023) |
| GlaxoSmithKline, LLC. | $49.21 | 3 | $0 (2020) |
| Radius Health, Inc. | $45.48 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $155.64 | 3 | Novo Nordisk Inc ($116.00) |
| 2023 | $58.13 | 3 | Bayer Healthcare Pharmaceuticals Inc. ($58.13) |
| 2022 | $123.07 | 2 | Novo Nordisk Inc ($105.00) |
| 2020 | $98.01 | 6 | PFIZER INC. ($33.44) |
| 2019 | $621.61 | 26 | AstraZeneca Pharmaceuticals LP ($374.97) |
| 2018 | $440.99 | 33 | PFIZER INC. ($167.69) |
| 2017 | $537.92 | 44 | PFIZER INC. ($152.75) |
All Payment Transactions
117 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/01/2024 | Novo Nordisk Inc | Ozempic (Drug) | Education | In-kind items and services | $116.00 | General |
| Category: Diabetes | ||||||
| 02/15/2024 | Chiesi USA, Inc. | CLEVIPREX (Drug), KENGREAL | Food and Beverage | Cash or cash equivalent | $16.27 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/31/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: PSYCHIATRY | ||||||
| 06/15/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Education | In-kind items and services | $19.62 | General |
| Category: Cardio-renal | ||||||
| 06/15/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Cardio-renal | ||||||
| 03/08/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Cardio-renal | ||||||
| 11/09/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Cardio-renal | ||||||
| 07/29/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $105.00 | General |
| Category: Diabetes | ||||||
| 02/25/2020 | Amgen Inc. | Aimovig (Biological), Repatha | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Neuroscience | ||||||
| 02/19/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/03/2020 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 01/28/2020 | PFIZER INC. | PREVNAR 13 (Biological) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: VACCINES | ||||||
| 01/14/2020 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BEXSERO | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: VACCINES | ||||||
| 01/07/2020 | Amgen Inc. | Aimovig (Biological), Repatha | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Neuroscience | ||||||
| 12/03/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $122.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/29/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/22/2019 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 10/14/2019 | PFIZER INC. | PREVNAR - 13 (Biological) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: VACCINES | ||||||
| 10/08/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: NEUROSCIENCE | ||||||
| 09/24/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/17/2019 | Merck Sharp & Dohme Corporation | PNEUMOVAX 23 (Biological), VAQTA, GARDASIL9 | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: VACCINE | ||||||
| 08/27/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/19/2019 | PFIZER INC. | PREVNAR - 13 (Biological) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 608 | 1,086 | $146,019 | $95,234 |
| 2022 | 8 | 455 | 860 | $127,423 | $86,500 |
| 2021 | 7 | 351 | 698 | $90,506 | $62,869 |
| 2020 | 10 | 437 | 892 | $103,139 | $61,182 |
Total Patients
1,851
Total Services
3,536
Medicare Billing
$305,784
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 399 | $53,905 | $38,445 | 71.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 82 | 188 | $32,195 | $23,746 | 73.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 88 | 88 | $18,744 | $11,738 | 62.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 86 | 86 | $12,516 | $7,079 | 56.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 57 | $6,326 | $3,849 | 60.8% |
| 99350 | Residence visit for established patient with high level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 12 | 27 | $6,840 | $3,532 | 51.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $7,900 | $3,274 | 41.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 69 | 69 | $1,271 | $1,219 | 95.9% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 62 | 62 | $1,142 | $1,092 | 95.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 11 | 50 | $3,801 | $928.28 | 24.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 13 | 17 | $1,240 | $194.72 | 15.7% |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | Office | 2023 | 19 | 19 | $140.03 | $137.18 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 103 | 391 | $52,824 | $38,472 | 72.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 76 | 151 | $25,859 | $18,862 | 72.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 88 | 88 | $18,744 | $12,251 | 65.4% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 77 | 77 | $11,207 | $6,496 | 58.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 52 | 89 | $9,877 | $6,401 | 64.8% |
| 99350 | Established patient home visit, typically 1 hour | Office | 2022 | 11 | 16 | $4,053 | $2,312 | 57.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $4,608 | $1,558 | 33.8% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2022 | 34 | 34 | $250.58 | $147.31 | 58.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 87 | 242 | $32,694 | $24,847 | 76.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 94 | 280 | $31,070 | $19,409 | 62.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 56 | 56 | $8,636 | $7,638 | 88.4% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Office | 2021 | 66 | 67 | $9,751 | $5,370 | 55.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 27 | $4,624 | $3,660 | 79.1% |
About Dr. Marcus Griffin, M.D
Dr. Marcus Griffin, M.D is a Legal Medicine healthcare provider based in Kihei, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780774174.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marcus Griffin, M.D has received a total of $2,035 in payments from pharmaceutical and medical device companies, with $155.64 received in 2024. These payments were reported across 117 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($1,895).
As a Medicare-enrolled provider, Griffin has provided services to 1,851 Medicare beneficiaries, totaling 3,536 services with total Medicare billing of $305,784. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Legal Medicine
- Location Kihei, HI
- Active Since 10/13/2006
- Last Updated 07/08/2007
- Taxonomy Code 173000000X
- Entity Type Individual
- NPI Number 1780774174
Products in Payments
- FARXIGA (Drug) $479.78
- CHANTIX (Drug) $218.98
- Ozempic (Drug) $116.00
- Rybelsus (Drug) $105.00
- PREVNAR - 13 (Biological) $82.50
- TOUJEO (Drug) $77.77
- LINZESS (Drug) $77.42
- Kerendia (Drug) $76.20
- BYDUREON (Drug) $68.93
- LYRICA (Drug) $62.50
- VIAGRA (Drug) $54.97
- QVAR (Drug) $50.55
- Tymlos (Biological) $45.48
- JANUVIA (Drug) $44.28
- ASMANEX (Drug) $41.44
- VRAYLAR (Drug) $40.94
- BEVESPI AEROSPHERE (Drug) $39.51
- Aimovig (Biological) $29.49
- SOLIQUA (Drug) $28.41
- AJOVY (Drug) $27.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.